1 2969 513 GENETIC AND EPIGENETIC REGULATION OF THE INNATE IMMUNE RESPONSE TO GOUT. GOUT IS A DISEASE CAUSED BY URIC ACID (UA) ACCUMULATION IN THE JOINTS, CAUSING INFLAMMATION. TWO UA FORMS - MONOSODIUM URATE (MSU) AND SOLUBLE URIC ACID (SUA) HAVE BEEN SHOWN TO INTERACT PHYSICALLY WITH INFLAMMASOMES, ESPECIALLY WITH THE NOD-LIKE RECEPTOR (NLR) FAMILY PYRIN DOMAIN CONTAINING 3 (NLRP3), ALBEIT THE ROLE OF THE IMMUNE RESPONSE TO UA IS POORLY UNDERSTOOD, GIVEN THAT ASYMPTOMATIC HYPERURICEMIA DOES ALSO EXIST. MACROPHAGE PHAGOCYTOSIS OF UA ACTIVATE NLRP3, LEAD TO CYTOKINES RELEASE, AND ULTIMATELY, LEAD TO CHEMOATTRACT NEUTROPHILS AND LYMPHOCYTES TO THE GOUT FLARE JOINT SPOT. GENETIC VARIANTS OF INFLAMMASOME GENES AND OF GENES ENCODING THEIR MOLECULAR PARTNERS MAY INFLUENCE HYPERURICEMIA AND GOUT SUSCEPTIBILITY, WHILE ALSO INFLUENCING OTHER COMORBIDITIES SUCH AS METABOLIC SYNDROME AND CARDIOVASCULAR DISEASES. IN THIS REVIEW, WE SUMMARIZE THE INFLAMMATORY RESPONSES IN ACUTE AND CHRONIC GOUT, SPECIFICALLY FOCUSING ON INNATE IMMUNE CELL MECHANISMS AND GENETIC AND EPIGENETIC CHARACTERISTICS OF PARTICIPATING MOLECULES. UNPRECEDENTLY, A NOVEL UA BINDING PROTEIN - THE NEURONAL APOPTOSIS INHIBITOR PROTEIN (NAIP) - IS SUGGESTED AS RESPONSIBLE FOR THE ASYMPTOMATIC HYPERURICEMIA PARADOX.ABBREVIATION: BETA2-INTEGRINS: LEUKOCYTE-SPECIFIC ADHESION MOLECULES; ABCG2: ATP-BINDING CASSETE FAMILY/BREAST CANCER-RESISTANT PROTEIN; ACR: AMERICAN COLLEGE OF RHEUMATOLOGY; AIM2: ABSENT IN MELANOMA 2, TYPE OF PATTERN RECOGNITION RECEPTOR; ALPK1: ALPHA-PROTEIN KINASE 1; ANGPTL2: ANGIOPOIETIN-LIKE PROTEIN 2; ASC: APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN; BIR: BACULOVIRUS INHIBITOR OF APOPTOSIS PROTEIN REPEAT; BIRC1: BACULOVIRUS IAP REPEAT-CONTAINING PROTEIN 1; BIRC2: BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 2; C5A: COMPLEMENT ANAPHYLATOXIN; CAMP: CYCLIC ADENOSINE MONOPHOSPHATE; CARD: CASPASE ACTIVATION AND RECRUITMENT DOMAINS; CARD8: CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 8; CASP1: CASPASE 1; CCL3: CHEMOKINE (C-C MOTIF) LIGAND 3; CD14: CLUSTER OF DIFFERENTIATION 14; CD44: CLUSTER OF DIFFERENTIATION 44; CG05102552: DNA-METHYLATION SITE, USUALLY CYTOSINE FOLLOWED BY GUANINE NUCLEOTIDES; CONTAINS ARBITRARY IDENTIFICATION CODE; CIDEC: CELL DEATH-INDUCING DNA FRAGMENTATION FACTOR-LIKE EFFECTOR FAMILY; CKD: CHRONIC KIDNEY DISEASE; CNV: COPY NUMBER VARIATION; CPT1A: CARNITINE PALMITOYL TRANSFERASE - TYPE 1A; CXCL1: CHEMOKINE (CXC MOTIF) LIGAND 1; DAMPS: DAMAGE ASSOCIATED MOLECULAR PATTERNS; DC: DENDRITIC CELLS; DNMT(1): MAINTENANCE DNA METHYLTRANSFERASE; EQTL: EXPRESSION QUANTITATIVE TRAIT LOCI; ERK1: EXTRACELLULAR SIGNAL-REGULATED KINASE 1; ERK2: EXTRACELLULAR SIGNAL-REGULATED KINASE 2; EULAR: EUROPEAN LEAGUE AGAINST RHEUMATISM; GMCSF: GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GWAS: GLOBAL WIDE ASSOCIATION STUDIES; H3K27ME3: TRI-METHYLATION AT THE 27TH LYSINE RESIDUE OF THE HISTONE H3 PROTEIN; H3K4ME1: MONO-METHYLATION AT THE 4TH LYSINE RESIDUE OF THE HISTONE H3 PROTEIN; H3K4ME3: TRI-METHYLATION AT THE 4TH LYSINE RESIDUE OF THE HISTONE H3 PROTEIN; HOTAIR: HUMAN GENE LOCATED BETWEEN HOXC11 AND HOXC12 ON CHROMOSOME 12; IKAPPABALPHA: CYTOPLASMATIC PROTEIN/NF-KAPPAB TRANSCRIPTION INHIBITOR; IAP: INHIBITORY APOPTOSIS PROTEIN; IFNGAMMA: INTERFERON GAMMA; IL-1BETA: INTERLEUKIN 1 BETA; IL-12: INTERLEUKIN 12; IL-17: INTERLEUKIN 17; IL18: INTERLEUKIN 18; IL1R1: INTERLEUKIN-1 RECEPTOR; IL-1RA: INTERLEUKIN-1 RECEPTOR ANTAGONIST; IL-22: INTERLEUKIN 22; IL-23: INTERLEUKIN 23; IL23R: INTERLEUKIN 23 RECEPTOR; IL-33: INTERLEUKIN 33; IL-6: INTERLEUKIN 6; IMP: INOSINE MONOPHOSPHATE; INSIG1: INSULIN-INDUCED GENE 1; JNK1: C-JUN N-TERMINAL KINASE 1; LNCRNA: LONG NON-CODING RIBONUCLEIC ACID; LRR: LEUCINE-RICH REPEATS; MIR: MATURE NON-CODING MICRORNAS MEASURING FROM 20 TO 24 NUCLEOTIDES, ANIMAL ORIGIN; MIR-1: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE; MIR-145: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE; MIR-146A: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE, "A" STANDS FOR MIR FAMILY; "A" FAMILY PRESENTS SIMILAR MIR SEQUENCE TO "B" FAMILY, BUT DIFFERENT PRECURSORS; MIR-20B: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE; "B" STANDS FOR MIR FAMILY; "B" FAMILY PRESENTS SIMILAR MIR SEQUENCE TO "A" FAMILY, BUT DIFFERENT PRECURSORS; MIR-221: MIR - FOLLOWED BY ARBITRARY IDENTIFICATION CODE; MIR-221-5P: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE; "5P" INDICATES DIFFERENT MATURE MIRNAS GENERATED FROM THE 5' ARM OF THE PRE-MIRNA HAIRPIN; MIR-223: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE; MIR-223-3P: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE; "3P" INDICATES DIFFERENT MATURE MIRNAS GENERATED FROM THE 3' ARM OF THE PRE-MIRNA HAIRPIN; MIR-22-3P: MIR FOLLOWED BY ARBITRARY IDENTIFICATION CODE, "3P" INDICATES DIFFERENT MATURE MIRNAS GENERATED FROM THE 3' ARM OF THE PRE-MIRNA HAIRPIN; MLKL: MIXED LINEAGE KINASE DOMAIN-LIKE PSEUDO KINASE; MM2P: INDUCTOR OF M2-MACROPHAGE POLARIZATION; MSU: MONOSODIUM URATE; MTOR: MAMMALIAN TARGET OF RAPAMYCIN; MYD88: MYELOID DIFFERENTIATION PRIMARY RESPONSE 88; N-3-PUFAS: N-3-POLYUNSATURATED FATTY-ACIDS; NACHT: ACRONYM FOR NAIP (NEURONAL APOPTOSIS INHIBITOR PROTEIN), C2TA (MHC CLASS 2 TRANSCRIPTION ACTIVATOR), HET-E (INCOMPATIBILITY LOCUS PROTEIN FROM PODOSPORA ANSERINA) AND TP1 (TELOMERASE-ASSOCIATED PROTEIN); NAIP: NEURONAL APOPTOSIS INHIBITORY PROTEIN (HUMAN); NAIP1: NEURONAL APOPTOSIS INHIBITORY PROTEIN TYPE 1 (MURINE); NAIP5: NEURONAL APOPTOSIS INHIBITORY PROTEIN TYPE 5 (MURINE); NAIP6: NEURONAL APOPTOSIS INHIBITORY PROTEIN TYPE 6 (MURINE); NBD: NUCLEOTIDE-BINDING DOMAIN; NEK7: SMALLEST NIMA-RELATED KINASE; NET: NEUTROPHIL EXTRACELLULAR TRAPS; NF-KAPPAB: NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS; NFIL3: NUCLEAR-FACTOR, INTERLEUKIN 3 REGULATED PROTEIN; NIIMA: NETWORK OF IMMUNITY IN INFECTION, MALIGNANCY, AND AUTOIMMUNITY; NLR: NOD-LIKE RECEPTOR; NLRA: NOD-LIKE RECEPTOR NLRA CONTAINING ACIDIC DOMAIN; NLRB: NOD-LIKE RECEPTOR NLRA CONTAINING BIR DOMAIN; NLRC: NOD-LIKE RECEPTOR NLRA CONTAINING CARD DOMAIN; NLRC4: NOD-LIKE RECEPTOR FAMILY CARD DOMAIN CONTAINING 4; NLRP: NOD-LIKE RECEPTOR NLRA CONTAINING PYD DOMAIN; NLRP1: NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE-RICH REPEAT, AND PYRIN DOMAIN CONTAINING 1; NLRP12: NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE-RICH REPEAT, AND PYRIN DOMAIN CONTAINING 12; NLRP3: NOD-LIKE RECEPTOR FAMILY PYRIN DOMAIN CONTAINING 3; NOD2: NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN; NRBP1: NUCLEAR RECEPTOR-BINDING PROTEIN; NRF2: NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2; OR: ODDS RATIO; P2X: GROUP OF MEMBRANE ION CHANNELS ACTIVATED BY THE BINDING OF EXTRACELLULAR; P2X7: P2X PURINOCEPTOR 7 GENE; P38: MEMBER OF THE MITOGEN-ACTIVATED PROTEIN KINASE FAMILY; PAMPS: PATHOGEN ASSOCIATED MOLECULAR PATTERS; PBMC: PERIPHERAL BLOOD MONONUCLEAR CELLS; PGGT1B: GERANYLGERANYL TRANSFERASE TYPE-1 SUBUNIT BETA; PHGDH: PHOSPHOGLYCERATE DEHYDROGENASE; PI3-K: PHOSPHO-INOSITOL; PPARGAMMA: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; PPARGC1B: PEROXISOME PROLIFERATIVE ACTIVATED RECEPTOR, GAMMA, COACTIVATOR 1 BETA; PR3: PROTEINASE 3 ANTIGEN; PRO-CASP1: INACTIVE PRECURSOR OF CASPASE 1; PRO-IL1BETA: INACTIVE PRECURSOR OF INTERLEUKIN 1 BETA; PRR: PATTERN RECOGNITION RECEPTORS; PYD: PYRIN DOMAIN; RAPTOR: REGULATORY ASSOCIATED PROTEIN OF MTOR COMPLEX 1; RAS: RENIN-ANGIOTENSIN SYSTEM; REDD1: REGULATED IN DNA DAMAGE AND DEVELOPMENT 1; ROS: REACTIVE OXYGEN SPECIES; RS000*G: SINGLE NUCLEAR POLYMORPHISM, "*G" IS RELATED TO SNP WHERE REPLACED NUCLEOTIDE IS GUANINE, USUALLY PRECEDED BY AN ID NUMBER; SLC2A9: SOLUTE CARRIER FAMILY 2, MEMBER 9; SLC7A11: SOLUTE CARRIER FAMILY 7, MEMBER 11; SMA: SMOOTH MUSCULAR ATROPHY; SMAC: SECOND MITOCHONDRIAL-DERIVED ACTIVATOR OF CASPASES; SNP: SINGLE NUCLEAR POLYMORPHISM; SP3: SPECIFICITY PROTEIN 3; ST2: SERUM STIMULATION-2; STK11: SERINE/THREONINE KINASE 11; SUA: SOLUBLE URIC ACID; SYK: SPLEEN TYROSINE KINASE; TAK1: TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE; TH1: TYPE 1 HELPER T CELLS; TH17: TYPE 17 HELPER T CELLS; TH2: TYPE 2 HELPER T CELLS; TH22: TYPE 22 HELPER T CELLS; TLR: TOOL-LIKE RECEPTOR; TLR2: TOLL-LIKE RECEPTOR 2; TLR4: TOLL-LIKE RECEPTOR 4; TNFALPHA: TUMOR NECROSIS FACTOR ALPHA; TNFR1: TUMOR NECROSIS FACTOR RECEPTOR 1; TNFR2: TUMOR NECROSIS FACTOR RECEPTOR 2; UA: URIC ACID; UBAP1: UBIQUITIN ASSOCIATED PROTEIN; ULT: URATE-LOWERING THERAPY; URAT1: URATE TRANSPORTER 1; VDAC1: VOLTAGE-DEPENDENT ANION-SELECTIVE CHANNEL 1. 2023 2 3492 39 IDENTIFICATION OF HISTONE DEACETYLASE 10 (HDAC10) INHIBITORS THAT MODULATE AUTOPHAGY IN TRANSFORMED CELLS. HISTONE DEACETYLASES (HDACS) ARE A FAMILY OF 18 EPIGENETIC MODIFIERS THAT FALL INTO 4 CLASSES. HISTONE DEACETYLASE INHIBITORS (HDACI) ARE VALID TOOLS TO ASSESS HDAC FUNCTIONS. HDAC6 AND HDAC10 BELONG TO THE CLASS IIB SUBGROUP OF THE HDAC FAMILY. THE TARGETS AND BIOLOGICAL FUNCTIONS OF HDAC10 ARE ILL-DEFINED. THIS LACK OF KNOWLEDGE IS DUE TO A LACK OF SPECIFIC AND POTENT HDAC10 INHIBITORS WITH CELLULAR ACTIVITY. HERE, WE HAVE SYNTHESIZED AND CHARACTERIZED PIPERIDINE-4-ACRYLHYDROXAMATES AS POTENT AND HIGHLY SELECTIVE INHIBITORS OF HDAC10. THIS WAS ACHIEVED BY TARGETING THE ACIDIC GATEKEEPER RESIDUE GLU274 OF HDAC10 WITH A BASIC PIPERIDINE MOIETY THAT MIMICS THE INTERACTION OF THE POLYAMINE SUBSTRATE OF HDAC10. WE HAVE CONFIRMED THE BINDING MODES OF SELECTED INHIBITORS USING X-RAY CRYSTALLOGRAPHY. PROMISING CANDIDATES WERE SELECTED BASED ON THEIR SPECIFICITY BY IN VITRO PROFILING USING RECOMBINANT HDACS. THE MOST PROMISING HDAC10 INHIBITORS 10C AND 13B WERE TESTED FOR SPECIFICITY IN ACUTE MYELOID LEUKEMIA (AML) CELLS WITH THE FLT3-ITD ONCOGENE. BY IMMUNOBLOT EXPERIMENTS WE ASSESSED THE HYPERACETYLATION OF HISTONES AND TUBULIN-ALPHA, WHICH ARE CLASS I AND HDAC6 SUBSTRATES, RESPECTIVELY. AS VALIDATED TEST FOR HDAC10 INHIBITION WE USED FLOW CYTOMETRY ASSESSING AUTOLYSOSOME FORMATION IN NEUROBLASTOMA AND AML CELLS. WE DEMONSTRATE THAT 10C AND 13B INHIBIT HDAC10 WITH HIGH SPECIFICITY OVER HDAC6 AND WITH NO SIGNIFICANT IMPACT ON CLASS I HDACS. THE ACCUMULATION OF AUTOLYSOSOMES IS NOT A CONSEQUENCE OF APOPTOSIS AND 10C AND 13B ARE NOT TOXIC FOR NORMAL HUMAN KIDNEY CELLS. THESE DATA SHOW THAT 10C AND 13B ARE NANOMOLAR INHIBITORS OF HDAC10 WITH HIGH SPECIFICITY. THUS, OUR NEW HDAC10 INHIBITORS ARE TOOLS TO IDENTIFY THE DOWNSTREAM TARGETS AND FUNCTIONS OF HDAC10 IN CELLS. 2022 3 3124 41 GHRELIN TREATMENT IMPROVES PHYSICAL DECLINE IN SARCOPENIA MODEL MICE THROUGH MUSCULAR ENHANCEMENT AND MITOCHONDRIAL ACTIVATION. CHRONIC KIDNEY DISEASE (CKD) IMPAIRS PHYSICAL PERFORMANCE IN HUMANS, WHICH LEADS TO A RISK OF ALL-CAUSE MORTALITY. IN OUR PREVIOUS STUDY, WE DEMONSTRATED THAT A REDUCTION IN MUSCLE MITOCHONDRIA RATHER THAN MUSCLE MASS WAS A MAJOR CAUSE OF PHYSICAL DECLINE IN 5/6 NEPHRECTOMIZED CKD MODEL MICE. BECAUSE GHRELIN ADMINISTRATION HAS BEEN REPORTED TO ENHANCE OXYGEN UTILIZATION IN SKELETAL MUSCLE, WE EXAMINED THE USEFULNESS OF GHRELIN FOR A RECOVERY OF PHYSICAL DECLINE IN 5/6 NEPHRECTOMIZED C57BL/6 MICE, FOCUSING ON THE EPIGENETIC MODIFICATION OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR-1ALPHA (PGC-1ALPHA), A MASTER REGULATOR OF MITOCHONDRIAL BIOGENESIS. THE MICE WERE INTRAPERITONEALLY ADMINISTERED ACYLATED GHRELIN (0.1 NMOL/GBW; THREE TIMES PER WEEK) FOR A MONTH. MUSCLE STRENGTH AND EXERCISE ENDURANCE WERE MEASURED BY USING A DYNAMOMETER AND TREADMILL, RESPECTIVELY. MITOCHONDRIAL DNA COPY NUMBER WAS DETERMINED BY QUANTITATIVE PCR. THE METHYLATION LEVELS OF THE CYTOSINE RESIDUE AT 260 BASE PAIRS UPSTREAM OF THE TRANSLATION INITIATION POINT (C-260) OF PGC-1ALPHA, WHICH HAS BEEN DEMONSTRATED TO DECREASE THE EXPRESSION, WAS EVALUATED BY METHYLATION-SPECIFIC PCR AND BISULFITE GENOMIC SEQUENCING METHODS AFTER THE GHRELIN ADMINISTRATION. GHRELIN ADMINISTRATION IMPROVED BOTH MUSCLE STRENGTH AND EXERCISE ENDURANCE IN THE MICE AND WAS ASSOCIATED WITH AN INCREASE IN MUSCLE MASS AND MUSCLE MITOCHONDRIAL CONTENT. GHRELIN ADMINISTRATION DECREASED THE METHYLATION RATIO OF C-260 OF PGC-1ALPHA IN THE SKELETAL MUSCLE AND INCREASED THE EXPRESSION. THEREFORE, GHRELIN ADMINISTRATION EFFECTIVELY REDUCED THE PHYSICAL DECLINE IN 5/6 NEPHRECTOMIZED MICE AND WAS ACCOMPANIED WITH AN INCREASED MITOCHONDRIAL CONTENT THROUGH DE-METHYLATION OF THE PROMOTER REGION OF PGC-1ALPHA IN THE MUSCLE. 2017 4 5760 58 SOLUBLE URIC ACID PRIMES TLR-INDUCED PROINFLAMMATORY CYTOKINE PRODUCTION BY HUMAN PRIMARY CELLS VIA INHIBITION OF IL-1RA. OBJECTIVES: THE STUDY OF THE PROINFLAMMATORY ROLE OF URIC ACID HAS FOCUSED ON THE EFFECTS OF ITS CRYSTALS OF MONOSODIUM URATE (MSU). HOWEVER, LITTLE IS KNOWN WHETHER URIC ACID ITSELF CAN DIRECTLY HAVE PROINFLAMMATORY EFFECTS. IN THIS STUDY, WE INVESTIGATE THE PRIMING EFFECTS OF URIC ACID EXPOSURE ON THE CYTOKINE PRODUCTION OF PRIMARY HUMAN CELLS UPON STIMULATION WITH GOUT-RELATED STIMULI. METHODS: PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) WERE HARVESTED FROM PATIENTS WITH GOUT AND HEALTHY VOLUNTEERS. CELLS WERE PRETREATED WITH OR WITHOUT URIC ACID IN SOLUBLE FORM FOR 24 H AND THEN STIMULATED FOR 24 H WITH TOLL-LIKE RECEPTOR (TLR)2 OR TLR4 LIGANDS IN THE PRESENCE OR ABSENCE OF MSU CRYSTALS. CYTOKINE PRODUCTION WAS MEASURED BY ELISA; MRNA LEVELS WERE ASSESSED USING QPCR. RESULTS: THE PRODUCTION OF INTERLEUKIN (IL)-1BETA AND IL-6 WAS HIGHER IN PATIENTS COMPARED WITH CONTROLS AND THIS CORRELATED WITH SERUM URATE LEVELS. PROINFLAMMATORY CYTOKINE PRODUCTION WAS SIGNIFICANTLY POTENTIATED WHEN CELLS FROM HEALTHY SUBJECTS WERE PRETREATED WITH URIC ACID. SURPRISINGLY, THIS WAS ASSOCIATED WITH A SIGNIFICANT DOWNREGULATION OF THE ANTI-INFLAMMATORY CYTOKINE IL-1 RECEPTOR ANTAGONIST (IL-1RA). THIS EFFECT WAS SPECIFIC TO STIMULATION BY URIC ACID AND WAS EXERTED AT THE LEVEL OF GENE TRANSCRIPTION. EPIGENETIC REPROGRAMMING AT THE LEVEL OF HISTONE METHYLATION BY URIC ACID WAS INVOLVED IN THIS EFFECT. CONCLUSIONS: IN THIS STUDY WE DEMONSTRATE A MECHANISM THROUGH WHICH HIGH CONCENTRATIONS OF URIC ACID (UP TO 50 MG/DL) INFLUENCE INFLAMMATORY RESPONSES BY FACILITATING IL-1BETA PRODUCTION IN PBMCS. WE SHOW THAT A MECHANISM FOR THE AMPLIFICATION OF IL-1BETA CONSISTS IN THE DOWNREGULATION OF IL-1RA AND THAT THIS EFFECT COULD BE EXERTED VIA EPIGENETIC MECHANISMS SUCH AS HISTONE METHYLATION. HYPERURICAEMIA CAUSES A SHIFT IN THE IL-1BETA/IL-1RA BALANCE PRODUCED BY PBMCS AFTER EXPOSURE TO MSU CRYSTALS AND TLR-MEDIATED STIMULI, AND THIS PHENOMENON IS LIKELY TO REINFORCE THE ENHANCED STATE OF CHRONIC INFLAMMATION. 2016 5 6015 45 THE ARGININE METHYLTRANSFERASE PRMT7 PROMOTES EXTRAVASATION OF MONOCYTES RESULTING IN TISSUE INJURY IN COPD. EXTRAVASATION OF MONOCYTES INTO TISSUE AND TO THE SITE OF INJURY IS A FUNDAMENTAL IMMUNOLOGICAL PROCESS, WHICH REQUIRES RAPID RESPONSES VIA POST TRANSLATIONAL MODIFICATIONS (PTM) OF PROTEINS. PROTEIN ARGININE METHYLTRANSFERASE 7 (PRMT7) IS AN EPIGENETIC FACTOR THAT HAS THE CAPACITY TO MONO-METHYLATE HISTONES ON ARGININE RESIDUES. HERE WE SHOW THAT IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS, PRMT7 EXPRESSION IS ELEVATED IN THE LUNG TISSUE AND LOCALIZED TO THE MACROPHAGES. IN MOUSE MODELS OF COPD, LUNG FIBROSIS AND SKIN INJURY, REDUCED EXPRESSION OF PRMT7 ASSOCIATES WITH DECREASED RECRUITMENT OF MONOCYTES TO THE SITE OF INJURY AND HENCE LESS SEVERE SYMPTOMS. MECHANISTICALLY, ACTIVATION OF NF-KAPPAB/RELA IN MONOCYTES INDUCES PRMT7 TRANSCRIPTION AND CONSEQUENTIAL MONO-METHYLATION OF HISTONES AT THE REGULATORY ELEMENTS OF RAP1A, WHICH LEADS TO INCREASED TRANSCRIPTION OF THIS GENE THAT IS RESPONSIBLE FOR ADHESION AND MIGRATION OF MONOCYTES. PERSISTENT MONOCYTE-DERIVED MACROPHAGE ACCUMULATION LEADS TO ALOX5 OVER-EXPRESSION AND ACCUMULATION OF ITS METABOLITE LTB4, WHICH TRIGGERS EXPRESSION OF ACSL4 A FERROPTOSIS PROMOTING GENE IN LUNG EPITHELIAL CELLS. CONCLUSIVELY, INHIBITION OF ARGININE MONO-METHYLATION MIGHT OFFER TARGETED INTERVENTION IN MONOCYTE-DRIVEN INFLAMMATORY CONDITIONS THAT LEAD TO EXTENSIVE TISSUE DAMAGE IF LEFT UNTREATED. 2022 6 5657 35 SEX-DEPENDENT PRONOCICEPTIVE ROLE OF SPINAL ALPHA(5) -GABA(A) RECEPTOR AND ITS EPIGENETIC REGULATION IN NEUROPATHIC RODENTS. EXTRASYNAPTIC ALPHA(5) -SUBUNIT CONTAINING GABA(A) (ALPHA(5) -GABA(A) ) RECEPTORS PARTICIPATE IN CHRONIC PAIN. PREVIOUSLY, WE REPORTED A SEX DIFFERENCE IN THE ACTION OF ALPHA(5) -GABA(A) RECEPTORS IN DYSFUNCTIONAL PAIN. HOWEVER, THE UNDERLYING MECHANISMS REMAIN UNKNOWN. THE AIM OF THIS STUDY WAS TO EXAMINE THIS SEXUAL DIMORPHISM IN NEUROPATHIC RODENTS AND THE MECHANISMS INVOLVED. FEMALE AND MALE WISTAR RATS OR ICR MICE WERE SUBJECTED TO NERVE INJURY FOLLOWED BY ALPHA(5) -GABA(A) RECEPTOR INVERSE AGONIST INTRATHECAL ADMINISTRATION, L-655,708. THE DRUG PRODUCED AN ANTIALLODYNIC EFFECT IN NERVE-INJURED FEMALE RATS AND MICE, AND A LOWER EFFECT IN MALES. WE HYPOTHESIZED THAT CHANGES IN ALPHA(5) -GABA(A) RECEPTOR, PROBABLY INFLUENCED BY HORMONAL AND EPIGENETIC STATUS, MIGHT UNDERLIE THIS SEX DIFFERENCE. THUS, WE PERFORMED QPCR AND WESTERN BLOT. NERVE INJURY INCREASED ALPHA(5) -GABA(A) MRNA AND PROTEIN IN FEMALE DORSAL ROOT GANGLIA (DRG) AND DECREASED THEM IN DRG AND SPINAL CORD OF MALES. TO INVESTIGATE THE HORMONAL INFLUENCE OVER ALPHA(5) -GABA(A) RECEPTOR ACTIONS, WE PERFORMED NERVE INJURY TO OVARIECTOMIZED RATS AND RECONSTITUTED THEM WITH 17BETA-ESTRADIOL (E2). OVARIECTOMY ABROGATED L-655,708 ANTIALLODYNIC EFFECT AND E2 RESTORED IT. OVARIECTOMY DECREASED ALPHA(5) -GABA(A) RECEPTOR AND ESTROGEN RECEPTOR ALPHA PROTEIN IN DRG OF NEUROPATHIC FEMALE RATS, WHILE E2 ENHANCED THEM. SINCE DNA METHYLATION MIGHT CONTRIBUTE TO ALPHA(5) -GABA(A) RECEPTOR DOWN-REGULATION IN MALES, WE EXAMINED CPG ISLAND DNA METHYLATION OF ALPHA(5) -GABA(A) RECEPTOR CODING GENE THROUGH PYROSEQUENCING. NERVE INJURY INCREASED METHYLATION IN MALE, BUT NOT FEMALE RATS. PHARMACOLOGICAL INHIBITION OF DNA METHYLTRANSFERASES INCREASED ALPHA(5) -GABA(A) RECEPTOR AND ENABLED L-655,708 ANTINOCICEPTIVE EFFECT IN MALE RATS. THESE RESULTS SUGGEST THAT ALPHA(5) -GABA(A) RECEPTOR IS A SUITABLE TARGET TO TREAT CHRONIC PAIN IN FEMALES. 2021 7 2885 33 G9A PARTICIPATES IN NERVE INJURY-INDUCED KCNA2 DOWNREGULATION IN PRIMARY SENSORY NEURONS. NERVE INJURY-INDUCED DOWNREGULATION OF VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT KCNA2 IN THE DORSAL ROOT GANGLION (DRG) IS CRITICAL FOR DRG NEURONAL EXCITABILITY AND NEUROPATHIC PAIN GENESIS. HOWEVER, HOW NERVE INJURY CAUSES THIS DOWNREGULATION IS STILL ELUSIVE. EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE 2, ALSO KNOWN AS G9A, METHYLATES HISTONE H3 ON LYSINE RESIDUE 9 TO PREDOMINANTLY PRODUCE A DYNAMIC HISTONE DIMETHYLATION, RESULTING IN CONDENSED CHROMATIN AND GENE TRANSCRIPTIONAL REPRESSION. WE SHOWED HERE THAT BLOCKING NERVE INJURY-INDUCED INCREASE IN G9A RESCUED KCNA2 MRNA AND PROTEIN EXPRESSION IN THE AXOTOMIZED DRG AND ATTENUATED THE DEVELOPMENT OF NERVE INJURY-INDUCED PAIN HYPERSENSITIVITY. MIMICKING THIS INCREASE DECREASED KCNA2 MRNA AND PROTEIN EXPRESSION, REDUCED KV CURRENT, AND INCREASED EXCITABILITY IN THE DRG NEURONS AND LED TO SPINAL CORD CENTRAL SENSITIZATION AND NEUROPATHIC PAIN-LIKE SYMPTOMS. G9A MRNA IS CO-LOCALIZED WITH KCNA2 MRNA IN THE DRG NEURONS. THESE FINDINGS INDICATE THAT G9A CONTRIBUTES TO NEUROPATHIC PAIN DEVELOPMENT THROUGH EPIGENETIC SILENCING OF KCNA2 IN THE AXOTOMIZED DRG. 2016 8 4546 47 MUTANT P53 REGULATES ENHANCER-ASSOCIATED H3K4 MONOMETHYLATION THROUGH INTERACTIONS WITH THE METHYLTRANSFERASE MLL4. MONOMETHYLATION OF HISTONE H3 LYSINE 4 (H3K4ME1) IS ENRICHED AT ENHANCERS THAT ARE PRIMED FOR ACTIVATION AND THE LEVELS OF THIS HISTONE MARK ARE FREQUENTLY ALTERED IN VARIOUS HUMAN CANCERS. YET, HOW ALTERATIONS IN H3K4ME1 ARE ESTABLISHED AND THE CONSEQUENCES OF THESE EPIGENETIC CHANGES IN TUMORIGENESIS ARE NOT WELL UNDERSTOOD. USING CHIP-SEQ IN HUMAN COLON CANCER CELLS, WE DEMONSTRATE THAT MUTANT P53 DEPLETION RESULTS IN DECREASED H3K4ME1 LEVELS AT ACTIVE ENHANCERS THAT REVEAL A STRIKING COLOCALIZATION OF MUTANT P53 AND THE H3K4 MONOMETHYLTRANSFERASE MLL4 FOLLOWING CHRONIC TUMOR NECROSIS FACTOR ALPHA (TNFALPHA) SIGNALING. WE FURTHER REVEAL THAT MUTANT P53 FORMS PHYSIOLOGICAL ASSOCIATIONS AND DIRECT INTERACTIONS WITH MLL4 AND PROMOTES THE ENHANCER BINDING OF MLL4, WHICH IS REQUIRED FOR TNFALPHA-INDUCIBLE H3K4ME1 AND HISTONE H3 LYSINE 27 ACETYLATION (H3K27AC) LEVELS, ENHANCER-DERIVED TRANSCRIPT (ERNA) SYNTHESIS, AND MUTANT P53-DEPENDENT TARGET GENE ACTIVATION. COMPLEMENTARY IN VITRO STUDIES WITH RECOMBINANT CHROMATIN AND PURIFIED PROTEINS DEMONSTRATE THAT BINDING OF THE MLL3/4 COMPLEX AND H3K4ME1 DEPOSITION IS ENHANCED BY MUTANT P53 AND P300-MEDIATED ACETYLATION, WHICH IN TURN REFLECTS A MLL3/4-DEPENDENT ENHANCEMENT OF MUTANT P53 AND P300-DEPENDENT TRANSCRIPTIONAL ACTIVATION. COLLECTIVELY, OUR FINDINGS ESTABLISH A MECHANISM IN WHICH MUTANT P53 COOPERATES WITH MLL4 TO REGULATE ABERRANT ENHANCER ACTIVITY AND TUMOR-PROMOTING GENE EXPRESSION IN RESPONSE TO CHRONIC IMMUNE SIGNALING. 2018 9 1163 41 CONTRIBUTION OF AMYGDALA HISTONE ACETYLATION IN EARLY LIFE STRESS-INDUCED VISCERAL HYPERSENSITIVITY AND EMOTIONAL COMORBIDITY. PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS) EXPERIENCE NOT ONLY ENHANCED VISCERAL PAIN BUT ALSO EMOTIONAL COMORBIDITIES, SUCH AS ANXIETY AND DEPRESSION. EARLY LIFE STRESS (ELS) IS A HIGH-RISK FOR THE DEVELOPMENT OF IBS. LITERATURES HAVE REPORTED AN IMPORTANT EPIGENETIC MODULATION IN SUSTAINING EXTRINSIC PHENOTYPES. THE AMYGDALA IS CLOSELY RELATED TO THE REGULATION OF VISCERAL FUNCTIONS AND EMOTIONAL EXPERIENCES. IN THIS STUDY, WE HYPOTHESIZED THAT ELS-INDUCED REPROGRAMMING INAPPROPRIATE ADAPTATION OF HISTONE ACETYLATION MODIFICATION IN THE AMYGDALA MAY RESULT IN VISCERAL HYPERSENSITIVITY AND ANXIETY-LIKE BEHAVIORS IN ELS RATS. TO TEST THIS HYPOTHESIS, THE MODEL OF ELS RATS WAS ESTABLISHED BY NEONATAL COLORECTAL DILATATION (CRD). VISCERAL HYPERSENSITIVITY WAS ASSESSED BASED ON THE ELECTROMYOGRAPHY RESPONSE OF THE ABDOMINAL EXTERNAL OBLIQUE MUSCLE TO CRD. EMOTIONAL COMORBIDITIES WERE EXAMINED USING THE ELEVATED PLUS MAZE TEST, OPEN FIELD TEST, AND SUCROSE PREFERENCE TEST. TRICHOSTATIN A (TSA) AND C646 WERE MICROINJECTED INTO THE CENTRAL AMYGDALA (CEA) INDIVIDUALLY TO INVESTIGATE THE EFFECTS OF DIFFERENT LEVELS OF HISTONE ACETYLATION MODIFICATION ON VISCERAL HYPERSENSITIVITY AND EMOTION. WE FOUND NEONATAL CRD RESULTED IN VISCERAL HYPERSENSITIVITY AND ANXIETY-LIKE BEHAVIORS AFTER ADULTHOOD. INHIBITING HISTONE DEACETYLASES (HDACS) IN THE CEA BY TSA ENHANCED VISCERAL SENSITIVITY BUT DID NOT AFFECT ANXIETY-LIKE BEHAVIORS, WHEREAS INHIBITING HAT BY C646 ATTENUATED VISCERAL HYPERSENSITIVITY IN ELS RATS. INTERESTINGLY, CEA TREATMENT WITH TSA INDUCED VISCERAL SENSITIVITY AND ANXIETY-LIKE BEHAVIORS IN THE CONTROL RATS. WESTERN BLOT SHOWED THAT THE EXPRESSIONS OF ACETYLATED 9 RESIDUE OF HISTONE 3 (H3K9) AND PROTEIN KINASE C ZETA TYPE (PKMZETA) WERE HIGHER IN THE ELS RATS COMPARED TO THOSE OF THE CONTROLS. THE ADMINISTRATION OF THE PKMZETA INHIBITOR ZIP INTO THE CEA ATTENUATED VISCERAL HYPERSENSITIVITY OF ELS RATS. FURTHERMORE, THE EXPRESSION OF AMYGDALA PKMZETA WAS ENHANCED BY TSA TREATMENT IN CONTROL RATS. FINALLY, WESTERN BLOT AND IMMUNOFLUORESCENCE RESULTS INDICATED THE DECREASE OF HDAC1 AND HDAC2 EXPRESSIONS, BUT NOT HDAC3 EXPRESSION, CONTRIBUTED TO THE ENHANCEMENT OF HISTONE ACETYLATION IN ELS RATS. OUR RESULTS SUPPORT OUR HYPOTHESIS THAT AMYGDALA-ENHANCED HISTONE ACETYLATION INDUCED BY STRESS IN EARLY LIFE RESULTS IN VISCERAL HYPERSENSITIVITY AND ANXIETY-LIKE BEHAVIORS IN ELS RATS, AND REVERSING THE ABNORMAL EPIGENETIC MECHANISMS MAY BE CRUCIAL TO RELIEVE CHRONIC SYMPTOMS IN ELS RATS. 2022 10 2370 40 EPIGENETIC REGULATION OF THE ALTERNATIVELY ACTIVATED MACROPHAGE PHENOTYPE. ALTERNATIVELY ACTIVATED (M2) MACROPHAGES PLAY CRITICAL ROLES IN DIVERSE CHRONIC DISEASES, INCLUDING PARASITE INFECTIONS, CANCER, AND ALLERGIC RESPONSES. HOWEVER, LITTLE IS KNOWN ABOUT THE ACQUISITION AND MAINTENANCE OF THEIR PHENOTYPE. WE REPORT THAT M2-MACROPHAGE MARKER GENES ARE EPIGENETICALLY REGULATED BY RECIPROCAL CHANGES IN HISTONE H3 LYSINE-4 (H3K4) AND HISTONE H3 LYSINE-27 (H3K27) METHYLATION; AND THE LATTER METHYLATION MARKS ARE REMOVED BY THE H3K27 DEMETHYLASE JUMONJI DOMAIN CONTAINING 3 (JMJD3). WE FOUND THAT CONTINUOUS INTERLEUKIN-4 (IL-4) TREATMENT LEADS TO DECREASED H3K27 METHYLATION, AT THE PROMOTER OF M2 MARKER GENES, AND A CONCOMITANT INCREASE IN JMJD3 EXPRESSION. FURTHERMORE, WE DEMONSTRATE THAT IL-4-DEPENDENT JMJD3 EXPRESSION IS MEDIATED BY STAT6, A MAJOR TRANSCRIPTION FACTOR OF IL-4-MEDIATED SIGNALING. AFTER IL-4 STIMULATION, ACTIVATED STAT6 IS INCREASED AND BINDS TO CONSENSUS SITES AT THE JMJD3 PROMOTER. INCREASED JMJD3 CONTRIBUTES TO THE DECREASE OF H3K27 DIMETHYLATION AND TRIMETHYLATION (H3K27ME2/3) MARKS AS WELL AS THE TRANSCRIPTIONAL ACTIVATION OF SPECIFIC M2 MARKER GENES. THE DECREASE IN H3K27ME2/3 AND INCREASE IN JMJD3 RECRUITMENT WERE CONFIRMED BY IN VIVO STUDIES USING A SCHISTOSOMA MANSONI EGG-CHALLENGED MOUSE MODEL, A WELL-STUDIED SYSTEM KNOWN TO SUPPORT AN M2 PHENOTYPE. COLLECTIVELY, THESE DATA INDICATE THAT CHROMATIN REMODELING IS MECHANISTICALLY IMPORTANT IN THE ACQUISITION OF THE M2-MACROPHAGE PHENOTYPE. 2009 11 2300 34 EPIGENETIC REGULATION OF BDNF EXPRESSION IN THE PRIMARY SENSORY NEURONS AFTER PERIPHERAL NERVE INJURY: IMPLICATIONS IN THE DEVELOPMENT OF NEUROPATHIC PAIN. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IS KNOWN TO BE UP-REGULATED IN THE DORSAL ROOT GANGLION (DRG) AFTER PERIPHERAL NERVE INJURY, AND TO CONTRIBUTE TO NEUROPATHIC PAIN. HERE, WE FOUND THAT THERMAL HYPERALGESIA AND MECHANICAL ALLODYNIA AT DAY 7 POST-INJURY WERE INHIBITED ONLY WHEN ANTI-BDNF ANTIBODY WAS INTRATHECALLY ADMINISTRATED AT DAY 2 POST-INJURY. CONSISTENT WITH BEHAVIORAL RESULTS, WESTERN BLOT ANALYSIS SHOWED THAT THE EXPRESSION LEVELS OF BDNF PROTEIN IN THE SPINAL DORSAL HORN WERE MARKEDLY INDUCED DURING EARLY STAGE POST-INJURY. MOREOVER, THE MAXIMAL INCREASE IN BDNF MRNA EXPRESSION IN THE DRG WAS OBSERVED AT DAY 1 POST-INJURY, AND SIGNIFICANTLY ELEVATED LEVELS WERE SUSTAINED FOR AT LEAST 14 DAYS. FOUR OF FIVE BDNF MRNA TRANSCRIPTS WERE UP-REGULATED AFTER NERVE INJURY, AND THE MOST INDUCIBLE TRANSCRIPT WAS EXON I. USING A CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAY, WE FOUND THAT NERVE INJURY PROMOTES HISTONE H3 AND H4 ACETYLATION, TRANSCRIPTIONALLY ACTIVE MODIFICATIONS, AT BDNF PROMOTER I AT DAY 1 POST-INJURY, AND THE LEVELS OF HISTONE ACETYLATION REMAIN ELEVATED FOR AT LEAST 7 DAYS. TAKEN TOGETHER, OUR FINDINGS SUGGEST THAT AN INITIAL INCREASE IN BDNF EXON I EXPRESSION CONTROLLED BY EPIGENETIC MECHANISMS MIGHT HAVE A CRUCIAL ROLE IN THE DEVELOPMENT OF NEUROPATHIC PAIN. 2013 12 2202 42 EPIGENETIC MODIFICATION OF MIR-10A REGULATES RENAL DAMAGE BY TARGETING CREB1 IN TYPE 2 DIABETES MELLITUS. EMERGING EVIDENCE HAS SHOWN THAT MICRORNA-MEDIATED GENE EXPRESSION MODULATION PLAYS A CRUCIAL ROLE IN THE PATHOGENESIS OF TYPE 2 DIABETES MELLITUS, BUT THE NOVEL MIRNAS INVOLVED IN TYPE 2 DIABETES AND ITS FUNCTIONAL REGULATORY MECHANISMS STILL NEED TO BE DETERMINED. IN THIS STUDY, WE ASSESSED THE ROLE OF MIR-10A IN EXTRACELLULAR MATRIX ACCUMULATION IN THE KIDNEY OF DIABETIC MELLITUS INDUCED BY COMBINING ADMINISTRATION OF CHRONIC HIGH FAT DIET (HFD) AND LOW DOSAGE OF STREPTOZOTOCIN (STZ, 35MG/KG). HERE, WE FOUND THAT HFD/STZ ADMINISTRATION DECREASED THE LEVEL OF MICRORNA (MIR-10A) EXPRESSION IN ICR STRAIN MICE. OVEREXPRESSION OF MIR-10A ALLEVIATED THE INCREASED RATIO OF URINE ALBUMIN-TO-CREATININE (ACR) RATIO OF HFD/STZ MICE. IN CONTRAST, KNOCKDOWN OF MIR-10A INCREASED THE RATIO OF KIDNEY ACR IN NAIVE MICE. FURTHERMORE, CAMP RESPONSE ELEMENT BINDING PROTEIN 1 (CREB1) WAS VALIDATED AS A TARGET OF MIR-10A IN VITRO AND IN VIVO. CREB1 AND ITS DOWNSTREAM FIBRONECTIN (FN, EXTRACELLULAR MATRIX) WERE INCREASED IN HFD/STZ-TREATED MICE, WHICH WAS REVERSED BY KIDNEY MIR-10A OVEREXPRESSION. THE CONTENT OF CREB1 AND FN WAS INCREASED BY MIR-10A KNOCKDOWN IN KIDNEY OF NAIVE MICE. FURTHERMORE, HISTONE DEACETYLASE 3 (HDAC3) WAS REVEALED TO BE INCREASED IN KIDNEY OF HFD/STZ MICE, ACCOMPANIED WITH THE AUGMENTATION OF ACR RATIO AND FN LEVEL. KNOCKDOWN OF HDAC3 WITH SIRNA SIGNIFICANTLY CAUSED THE INCREASE OF MIR-10A, RESULTING IN THE DECREASE IN CREB1 AND FN EXPRESSION IN KIDNEY OF HFD/STZ MICE. CONTRARILY, HDAC3 OVEREXPRESSION MEDIATED BY LENTIVIRUS DECREASED MIR-10A CONTENT, AND ENHANCED ACR VALUE, CREB1 AND FN FORMATION IN NAIVE MICE. COLLECTIVELY, THESE RESULTS ELUCIDATE THAT HDAC3/MIR-10A/CREB1 SERVES AS A NEW MECHANISM UNDERLYING KIDNEY INJURY, PROVIDING POTENTIAL THERAPEUTIC TARGETS IN TYPE 2 DIABETES. 2016 13 5480 33 RESVERATROL REVERSES MORPHINE-INDUCED NEUROINFLAMMATION IN MORPHINE-TOLERANT RATS BY REVERSAL HDAC1 EXPRESSION. BACKGROUND/PURPOSE: WE PREVIOUSLY SHOWED THAT SUBSEQUENT INTRATHECAL (I.T.) INJECTION OF RESVERATROL (30 MUG) SIGNIFICANTLY REVERSES MORPHINE-EVOKED NEUROINFLAMMATION IN MORPHINE-TOLERANT RATS. THE PRESENT STUDY EXAMINED THE UNDERLYING MECHANISM. METHODS: MALE WISTAR RATS WERE IMPLANTED WITH TWO I.T. CATHETERS, ONE OF WHICH WAS CONNECTED TO A MINIOSMOTIC PUMP AND USED FOR MORPHINE (15 MUG/H) OR SALINE INFUSION FOR 120 HOURS. TO EXAMINE THE EFFECTS ON SPINAL CORD EXPRESSION OF HISTONE DEACETYLASE 1 (HDAC1), THE INFLAMMATORY CYTOKINE TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA), AND TNF RECEPTOR (TNFR) 1 AND TNFR2 DURING TOLERANCE INDUCTION, A TAIL-FLICK TEST WAS PERFORMED PRIOR TO INFUSION AND AFTER 24 HOURS, 48 HOURS, 72 HOURS, 96 HOURS, AND 120 HOURS OF INFUSION. RESULTS: RESVERATROL TREATMENT PRIOR TO MORPHINE CHALLENGE RESTORED THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN MORPHINE-TOLERANT RATS AND REVERSED THE MORPHINE INFUSION-INDUCED INCREASE IN HDAC1, TNF-ALPHA, AND TNFR1 EXPRESSION. MOREOVER, CHRONIC MORPHINE INFUSION INCREASED TNFR1-SPECIFIC EXPRESSION IN NEURON IN MORPHINE-TOLERANT RAT SPINAL CORDS, AND THIS EFFECT WAS ALMOST COMPLETELY INHIBITED BY RESVERATROL TREATMENT PRIOR TO MORPHINE CHALLENGE. CONCLUSION: RESVERATROL RESTORES THE ANTINOCICEPTIVE EFFECT OF MORPHINE BY REVERSING MORPHINE INFUSION-INDUCED SPINAL CORD NEUROINFLAMMATION AND INCREASE IN TNFR1 EXPRESSION. THE REVERSAL OF THE MORPHINE-INDUCED INCREASE IN TNFR1 EXPRESSION BY RESVERATROL IS PARTIALLY DUE TO REVERSAL OF THE MORPHINE INFUSION-INDUCED INCREASE IN HDAC1 EXPRESSION. RESVERATROL PRETREATMENT CAN BE USED AS AN ADJUVANT IN CLINICAL PAIN MANAGEMENT FOR PATIENTS WHO NEED LONG-TERM MORPHINE TREATMENT OR WITH NEUROPATHIC PAIN. 2016 14 2326 40 EPIGENETIC REGULATION OF HOTAIR IN ADVANCED CHRONIC MYELOID LEUKEMIA. PURPOSE: CHRONIC MYELOID LEUKEMIA (CML) ACCOUNTS FOR ~10% OF LEUKEMIA CASES, AND ITS PROGRESSION INVOLVES EPIGENETIC GENE REGULATION. THIS STUDY INVESTIGATED EPIGENETIC REGULATION OF HOTAIR AND ITS TARGET MICRORNA, MIR-143, IN ADVANCED CML. PATIENTS AND METHODS: WE FIRST ISOLATED BONE MARROW MONONUCLEAR CELLS FROM 70 PATIENTS WITH DIFFERENT PHASES OF CML AND FROM HEALTHY DONORS AS NORMAL CONTROL; WE ALSO CULTURED K562 AND KCL22 CELLS, TREATED WITH DEMETHYLATION DRUG; MTT ASSAY, FLOW CYTOMETRY, QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QPCR), METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP), WESTERN BLOT, LUCIFERASE ASSAY, RNA PULL-DOWN ASSAY AND RNA-BINDING PROTEIN IMMUNOPRECIPITATION (RIP) ASSAY WERE PERFORMED. RESULT: AS MEASURED BY QPCR, HOTAIR EXPRESSION IN K562 CELLS, KCL22 CELLS, AND SAMPLES FROM CASES OF ADVANCED-STAGE CML INCREASED WITH LEVELS OF SEVERAL DNA METHYLTRANSFERASES AND HISTONE DEACETYLATES, INCLUDING DNMT1, DNMT3A, HDAC1, EZH2, AND LSD1, AND MIR-143 LEVELS WERE DECREASED AND HOTAIR LEVELS WERE INCREASED. TREATMENT WITH 5-AZACYTIDINE, A DNA METHYLATION INHIBITOR, DECREASED DNMT1, DNMT3A, HDAC1, EZH2, LSD1 MRNA, PROTEIN LEVELS, AND HOTAIR MRNA LEVELS BUT INCREASED MIR-143 LEVELS. HOTAIR KNOCKDOWN AND MIR-143 OVEREXPRESSION BOTH INHIBITED PROLIFERATION AND PROMOTED APOPTOSIS IN KCL22 AND K562 CELLS THROUGH THE PI3K/AKT PATHWAY. RNA PULL-DOWN, MASS SPECTROMETRY, AND RIP ASSAYS SHOWED THAT HOTAIR INTERACTED WITH EZH2 AND LSD1. A DUAL-LUCIFERASE ASSAY DEMONSTRATED THAT HOTAIR INTERACTED WITH MIR-143. CONCLUSION: OUR FINDINGS DEMONSTRATE THE KEY EPIGENETIC INTERACTIONS OF HOTAIR RELATED TO CML PROGRESSION AND SUGGEST HOTAIR AS A POTENTIAL THERAPEUTIC TARGET FOR ADVANCED CML. FURTHERMORE, OUR RESULTS SUPPORT THE USE OF DEMETHYLATION DRUGS AS A CML TREATMENT STRATEGY. 2018 15 5976 30 TET1-DEPENDENT EPIGENETIC MODIFICATION OF BDNF EXPRESSION IN DORSAL HORN NEURONS MEDIATES NEUROPATHIC PAIN IN RATS. TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 (TET1) MEDIATES THE CONVERSION OF 5-METHYLCYTOSINE (5 MC) TO 5-HYDROXYMETHYLCYTOSINE (5 HMC), HENCE PROMOTING DNA DEMETHYLATION. ALTHOUGH RECENT STUDIES HAVE LINKED THE DNA DEMETHYLATION OF SPECIFIC GENES TO PAIN HYPERSENSITIVITY, THE ROLE OF SPINAL TET1-DEPENDENT DNA DEMETHYLATION IN NOCICEPTION HYPERSENSITIVITY DEVELOPMENT REMAINS ELUSIVE. HERE, WE REPORT CORRELATED WITH BEHAVIORAL ALLODYNIA, SPINAL NERVE LIGATION (SNL) UPREGULATED TET1 EXPRESSION IN DORSAL HORN NEURONS THAT HYDROXYLATE 5 MC TO 5 HMC AT CPG DINUCLEOTIDES IN THE BDNF PROMOTER TO PROMOTE SPINAL BDNF EXPRESSION AT DAY 7 AFTER OPERATION. FOCAL KNOCKDOWN OF SPINAL TET1 EXPRESSION DECREASED TET1 BINDING AND 5 HMC ENRICHMENT, FURTHER INCREASED 5 MC ENRICHMENT AT CPG SITES IN THE BDNF PROMOTER AND DECREASED SPINAL BDNF EXPRESSION ACCOMPANIED BY THE ALLEVIATION OF THE DEVELOPED ALLODYNIA. MOREOVER, AT DAY 7 AFTER OPERATION, SNL-ENHANCED TET1 EXPRESSION ALSO INHIBITED THE BINDING OF DNA METHYLTRANSFERASES (DNMTS, I.E., DNMT1, DNMT3A, AND DNMT3B) TO THE BDNF PROMOTER, A REQUIREMENT FOR TRANSCRIPTIONAL SILENCING BY CATALYSING 5-CYTOSINE (5C) TO 5 MC. TOGETHER, THESE DATA SUGGEST AT CPG SITES OF THE BDNF PROMOTER, SNL-ENHANCED TET1 EXPRESSION PROMOTES DNA DEMETHYLATION BOTH BY CONVERTING 5 MC TO 5 HMC AND INHIBITING DNMT BINDING TO REGULATE SPINAL BDNF EXPRESSION, HENCE CONTRIBUTING TO BEHAVIORAL ALLODYNIA DEVELOPMENT. 2016 16 5206 38 PRENATAL STRESS INDUCES LONG-TERM BEHAVIORAL SEX-DEPENDENT CHANGES IN RATS OFFSPRING: THE ROLE OF THE HPA AXIS AND EPIGENETICS. PRECLINICAL GENETIC STUDIES HAVE RELATED STRESS EARLY EXPOSURES WITH CHANGES IN GENE REGULATORY MECHANISMS, INCLUDING EPIGENETIC ALTERATIONS, SUCH AS MODIFICATIONS OF DNA METHYLATION, HISTONE DEACETYLATION, AND HISTONES ACETYLATION. THIS STUDY EVALUATES THE EFFECTS OF PRENATAL STRESS ON THE BEHAVIOR, HYPOTHALAMUS-PITUITARY-ADRENAL (HPA)-AXIS, AND EPIGENETIC PARAMETERS IN STRESSED DAMS AND THEIR OFFSPRING. THE RATS WERE SUBJECTED TO A PROTOCOL OF CHRONIC UNPREDICTABLE MILD STRESS ON THE FOURTEENTH DAY OF PREGNANCY UNTIL THE BIRTH OF OFFSPRING. AFTER BIRTH, MATERNAL CARE WAS EVALUATED FOR SIX DAYS. FOLLOWING WEANING, THE LOCOMOTOR AND DEPRESSIVE-LIKE BEHAVIORS OF THE DAMS AND THEIR OFFSPRING (60 DAYS OLD) WERE ASSESSED. THE HPA AXIS PARAMETERS WERE EVALUATED IN SERUM FROM DAMS AND OFFSPRING, AND EPIGENETIC PARAMETERS (HISTONE ACETYLTRANSFERASE (HAT), HISTONE DEACETYLASE (HDAC), DNA METHYLTRANSFERASE (DNMT) ACTIVITIES, AND THE LEVELS OF HISTONE H3 ACETYLATED AT LYSINE RESIDUE 9 (H3K9AC) AND HISTONE 3 ACETYLATED AT LYSINE RESIDUE 14 (H3K14AC)) WERE ASSESSED IN DAMS' AND OFFSPRING' BRAINS. PRENATAL STRESS DID NOT SIGNIFICANTLY INFLUENCE MATERNAL CARE; HOWEVER, IT INDUCED MANIC BEHAVIOR IN FEMALE OFFSPRING. THESE BEHAVIORAL ALTERATIONS IN THE OFFSPRING WERE ACCOMPANIED BY HYPERACTIVITY OF THE HPA-AXIS, EPIGENETIC ADAPTATIONS IN THE ACTIVITY OF HDAC AND DNMT, AND ACETYLATION IN THE HISTONES H3K9 AND H3K14. IN ADDITION, THE PRENATAL STRESSED FEMALE OFFSPRING SHOWED INCREASED LEVELS OF ACTH COMPARED TO THEIR MALE COUNTERPART. OUR FINDINGS REINFORCE THE IMPACT OF PRENATAL STRESS ON BEHAVIOR, STRESS RESPONSE, AND EPIGENETIC PROFILE OF OFFSPRING. 2023 17 3604 39 IMPROVEMENT OF PHYSICAL DECLINE THROUGH COMBINED EFFECTS OF MUSCLE ENHANCEMENT AND MITOCHONDRIAL ACTIVATION BY A GASTRIC HORMONE GHRELIN IN MALE 5/6NX CKD MODEL MICE. BECAUSE A PHYSICAL DECLINE CORRELATES WITH AN INCREASED RISK OF A WIDE RANGE OF DISEASE AND MORBIDITY, AN IMPROVEMENT OF PHYSICAL PERFORMANCE IS EXPECTED TO BRING SIGNIFICANT CLINICAL BENEFITS. THE PRIMARY CAUSE OF PHYSICAL DECLINE IN 5/6 NEPHRECTOMIZED (5/6NX) CHRONIC KIDNEY DISEASE MODEL MICE HAS BEEN REGARDED AS A DECREASE IN MUSCLE MASS; HOWEVER, OUR RECENT STUDY SHOWED THAT A DECREASE IN MUSCLE MITOCHONDRIA PLAYS A CRITICAL ROLE. IN THE PRESENT STUDY, WE EXAMINED THE EFFECTS OF A GASTRIC HORMONE GHRELIN, WHICH HAS BEEN REPORTED TO PROMOTE MUSCLE MITOCHONDRIAL OXIDATION, ON THE PHYSICAL DECLINE IN THE CHRONIC KIDNEY DISEASE MODEL MICE, FOCUSING ON THE EPIGENETIC MODULATIONS OF A MITOCHONDRIAL ACTIVATOR GENE, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA COACTIVATOR-1ALPHA (PGC-1ALPHA). GHRELIN TREATMENT IMPROVED A DECLINE IN EXERCISE ENDURANCE OF 5/6NX MICE, ASSOCIATED WITH AN INCREASE IN BOTH OF THE MUSCLE MASS AND MITOCHONDRIAL AMOUNT. THE EXPRESSION LEVEL OF PGC-1ALPHA WAS DECREASED IN THE SKELETAL MUSCLE OF 5/6NX MICE, WHICH WAS ASSOCIATED WITH AN INCREASE IN THE METHYLATION RATIO OF THE CYTOSINE RESIDUE AT 260 BASE PAIRS UPSTREAM OF THE INITIATION POINT. CONVERSELY, GHRELIN TREATMENT DE-METHYLATED THE CYTOSINE RESIDUE AND INCREASED THE EXPRESSION OF PGC-1ALPHA. A REPRESENTATIVE MUSCLE ANABOLIC FACTOR, IGF-1, DID NOT AFFECT THE EXPRESSION OF PGC-1ALPHA AND MUSCLE MITOCHONDRIAL AMOUNT, ALTHOUGH IT INCREASED MUSCLE MASS. AS A RESULT, IGF-1 TREATMENT IN 5/6NX MICE DID NOT INCREASE THE DECREASED EXERCISE ENDURANCE AS EFFECTIVELY AS GHRELIN TREATMENT DID. THESE FINDINGS INDICATE AN ADVANTAGE OF GHRELIN TREATMENT FOR A RECOVERY OF PHYSICAL DECLINE. 2015 18 2910 41 GENE EXPRESSION PROFILING OF EPIGENETIC CHROMATIN MODIFICATION ENZYMES AND HISTONE MARKS BY CIGARETTE SMOKE: IMPLICATIONS FOR COPD AND LUNG CANCER. CHROMATIN-MODIFYING ENZYMES MEDIATE DNA METHYLATION AND HISTONE MODIFICATIONS ON RECRUITMENT TO SPECIFIC TARGET GENE LOCI IN RESPONSE TO VARIOUS STIMULI. THE KEY ENZYMES THAT REGULATE CHROMATIN ACCESSIBILITY FOR MAINTENANCE OF MODIFICATIONS IN DNA AND HISTONES, AND FOR MODULATION OF GENE EXPRESSION PATTERNS IN RESPONSE TO CIGARETTE SMOKE (CS), ARE NOT KNOWN. WE HYPOTHESIZE THAT CS EXPOSURE ALTERS THE GENE EXPRESSION PATTERNS OF CHROMATIN-MODIFYING ENZYMES, WHICH THEN AFFECTS MULTIPLE DOWNSTREAM PATHWAYS INVOLVED IN THE RESPONSE TO CS. WE HAVE, THEREFORE, ANALYZED CHROMATIN-MODIFYING ENZYME PROFILES AND VALIDATED BY QUANTITATIVE REAL-TIME PCR (QPCR). WE ALSO PERFORMED IMMUNOBLOT ANALYSIS OF TARGETED HISTONE MARKS IN C57BL/6J MICE EXPOSED TO ACUTE AND SUBCHRONIC CS, AND OF LUNGS FROM NONSMOKERS, SMOKERS, AND PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). WE FOUND A SIGNIFICANT INCREASE IN EXPRESSION OF SEVERAL CHROMATIN MODIFICATION ENZYMES, INCLUDING DNA METHYLTRANSFERASES, HISTONE ACETYLTRANSFERASES, HISTONE METHYLTRANSFERASES, AND SET DOMAIN PROTEINS, HISTONE KINASES, AND UBIQUITINASES. OUR QPCR VALIDATION DATA REVEALED A SIGNIFICANT DOWNREGULATION OF DNMT1, DNMT3A, DNMT3B, HDAC2, HDAC4, HAT1, PRMT1, AND AURKB WE IDENTIFIED TARGETED CHROMATIN HISTONE MARKS (H3K56AC AND H4K12AC), WHICH ARE INDUCED BY CS. THUS CS-INDUCED GENOTOXIC STRESS DIFFERENTIALLY AFFECTS THE EXPRESSION OF EPIGENETIC MODULATORS THAT REGULATE TRANSCRIPTION OF TARGET GENES VIA DNA METHYLATION AND SITE-SPECIFIC HISTONE MODIFICATIONS. THIS MAY HAVE IMPLICATIONS IN DEVISING EPIGENETIC-BASED THERAPIES FOR COPD AND LUNG CANCER. 2016 19 2476 39 EPIGENETIC UPREGULATION OF CCL2 AND CCL3 VIA HISTONE MODIFICATIONS IN INFILTRATING MACROPHAGES AFTER PERIPHERAL NERVE INJURY. TO GAIN INSIGHT INTO THE EPIGENETIC REGULATION OF CC-CHEMOKINE LIGAND (CCL) 2 AND CCL3, KEY PLAYERS IN THE PERIPHERAL SENSITIZATION LEADING TO NEUROPATHIC PAIN, WE EXAMINED THE RELATIONSHIP BETWEEN HISTONE H3 MODIFICATION AND THE UPREGULATION OF THESE MOLECULES USING A MOUSE MODEL OF NEUROPATHIC PAIN AFTER PARTIAL SCIATIC NERVE LIGATION (PSL). WE FOUND THAT CIRCUITING BONE MARROW (BM)-DERIVED MACROPHAGES INFILTRATED INTO THE INJURED SCIATIC NERVE (SCN) USING ENHANCED GREEN FLUORESCENT PROTEIN CHIMERIC MICE. THE MRNA LEVELS OF CCL2, CCL3 AND THEIR RECEPTORS (CCR2 AND CCR1/CCR5, RESPECTIVELY) WERE INCREASED IN THE INJURED SCN. CHROMATIN IMMUNOPRECIPITATION ASSAY REVEALED THAT LEVELS OF LYSINE 9-ACETYLATED HISTONE H3 (H3K9AC) AND LYSINE 4-TRIMETHYLATED H3 (H3K4ME(3)) IN THE PROMOTER REGIONS OF THE CCL2 AND CCL3 GENES WERE INCREASED IN THE INJURED SCN AFTER PSL, INDICATING THE ENHANCEMENT OF GENE EXPRESSION. IMMUNOREACTIVITY FOR H3K9AC AND H3K4ME(3) WAS LOCALIZED IN THE NUCLEI OF INFILTRATING BM-DERIVED CELLS AND CCL-EXPRESSING CELLS IN THE INJURED SCN. WE OBSERVED H3K9AC AND H3K4ME(3) MAINLY IN THE NUCLEI OF RECRUITED MACROPHAGES ON DAY 7 AFTER PSL. FURTHERMORE, UPREGULATION OF CCLS AND CCRS WERE SUPPRESSED BY HISTONE ACETYLTRANSFERASE INHIBITOR, ANACARDIC ACID. TAKEN TOGETHER, OUR FINDINGS DEMONSTRATE THAT CCL2 AND CCL3 ARE UPREGULATED IN THE INJURED PERIPHERAL NERVE THROUGH EPIGENETIC HISTONE MODIFICATION IN INFILTRATING IMMUNE CELLS SUCH AS MACROPHAGES. THESE CHEMOKINE CASCADES MAY SUBSEQUENTLY ELICIT CHRONIC NEUROINFLAMMATION FOLLOWING NERVE INJURY. 2013 20 2884 35 G9A IS ESSENTIAL FOR EPIGENETIC SILENCING OF K(+) CHANNEL GENES IN ACUTE-TO-CHRONIC PAIN TRANSITION. NEUROPATHIC PAIN IS A DEBILITATING CLINICAL PROBLEM AND DIFFICULT TO TREAT. NERVE INJURY CAUSES A LONG-LASTING REDUCTION IN K(+) CHANNEL EXPRESSION IN THE DORSAL ROOT GANGLION (DRG), BUT LITTLE IS KNOWN ABOUT THE EPIGENETIC MECHANISMS INVOLVED. WE FOUND THAT NERVE INJURY INCREASED DIMETHYLATION OF LYS9 ON HISTONE H3 (H3K9ME2) AT KCNA4, KCND2, KCNQ2 AND KCNMA1 PROMOTERS BUT DID NOT AFFECT LEVELS OF DNA METHYLATION ON THESE GENES IN DRGS. NERVE INJURY INCREASED ACTIVITY OF EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE-2 (G9A), HISTONE DEACETYLASES AND ENHANCER OF ZESTE HOMOLOG-2 (EZH2), BUT ONLY G9A INHIBITION CONSISTENTLY RESTORED K(+) CHANNEL EXPRESSION. SELECTIVE KNOCKOUT OF THE GENE ENCODING G9A IN DRG NEURONS COMPLETELY BLOCKED K(+) CHANNEL SILENCING AND CHRONIC PAIN DEVELOPMENT AFTER NERVE INJURY. REMARKABLY, RNA SEQUENCING ANALYSIS REVEALED THAT G9A INHIBITION NOT ONLY REACTIVATED 40 OF 42 SILENCED GENES ASSOCIATED WITH K(+) CHANNELS BUT ALSO NORMALIZED 638 GENES DOWN- OR UPREGULATED BY NERVE INJURY. THUS G9A HAS A DOMINANT FUNCTION IN TRANSCRIPTIONAL REPRESSION OF K(+) CHANNELS AND IN ACUTE-TO-CHRONIC PAIN TRANSITION AFTER NERVE INJURY. 2015